Enhabit (EHAB) Q3 2025 Earnings
Reported Nov 5, 2025 at 4:17 PM ET · SEC Source
Q3 25 EPS
$0.17
BEAT +42.38%
Est. $0.12
Q3 25 Revenue
$263.6M
MISS 1.33%
Est. $267.1M
vs S&P Since Q3 25
+55.1%
BEATING MARKET
EHAB +67.3% vs S&P +12.1%
Market Reaction
Did EHAB Beat Earnings? Q3 2025 Results
Enhabit Home Health & Hospice delivered a sharply better-than-expected bottom line in Q3 2025, with adjusted diluted EPS of $0.17 beating the $0.12 consensus by 42.38%, even as revenue came in just slightly below expectations. Net service revenue ros… Read more Enhabit Home Health & Hospice delivered a sharply better-than-expected bottom line in Q3 2025, with adjusted diluted EPS of $0.17 beating the $0.12 consensus by 42.38%, even as revenue came in just slightly below expectations. Net service revenue rose 3.9% year over year to $263.60 million, missing the $267.14 million consensus by 1.33%, partly due to a temporary volume disruption from a national payer contract renegotiation that weighed on the home health segment in late Q2 and early Q3. The real story was hospice, where a deliberate de novo expansion strategy, with the company on track to open 10 new locations in 2025, drove a 20.0% revenue surge to a record $63.10 million and a 72.0% jump in segment Adjusted EBITDA to $17.20 million. Consolidated Adjusted EBITDA grew 10.2% to $27.00 million, while the company reduced its leverage ratio to 3.9x from 5.4x a year earlier. Looking ahead, Enhabit narrowed its full-year guidance, raising the Adjusted EBITDA floor to $106 million to $109 million and Adjusted EPS to $0.50 to $0.56.
Key Takeaways
- • Hospice ADC grew 12.6% year over year, with ADC increasing sequentially every quarter since Q1 2024
- • Home health non-Medicare admissions increased 10.4% year over year
- • Medicare ADC decline stabilized significantly to 1.4% vs. 14.1% decline in prior year quarter
- • Hospice cost per patient day improved 3.1% year over year on clinical productivity gains
- • Home health cost per patient day improved 2.1% year over year on better staff optimization
- • G&A expenses as a percentage of revenue improved 90 basis points year over year
- • Consolidated Adjusted EBITDA grew 10.2% year over year to $27.0 million
- • Temporary volume disruption from national payer contract renegotiation in late Q2/early Q3 impacted home health revenue
EHAB YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
EHAB Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our third quarter results reflect strong execution on our core strategic priorities, with year-over-year growth in revenue, census and Adjusted EBITDA. This progress allowed us to further reduce our bank debt and strengthen the balance sheet during the quarter.”
— Barb Jacobsmeyer, Q3 2025 Earnings Press Release
EHAB Earnings Trends
EHAB vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
EHAB EPS Trend
Earnings per share: estimate vs actual
EHAB Revenue Trend
Quarterly revenue: estimate vs actual
EHAB Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 MISS FY | $0.15 | $0.14 | -8.44% | $270.4M | -0.06% |
| FY Full Year | $0.56 | $0.53 | -5.88% | $1.06B | -0.01% |
| Q3 25 BEAT | $0.12 | $0.17 | +42.38% | $263.6M | -1.33% |
| Q2 25 BEAT | $0.10 | $0.13 | +30.78% | $266.1M | +1.03% |
| Q1 25 BEAT | $0.06 | $0.10 | +60.26% | $259.9M | -2.33% |